AI assistant
GALECTIN THERAPEUTICS INC — Director's Dealing 2018
Jan 30, 2018
33422_dirs_2018-01-29_5572c638-3dd2-4f00-9b72-48016d2674f1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-01-25
Reporting Person: 10X Fund, L.P. (10% Owner)
Reporting Person: 10X Capital Management, LLC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-01-25 | Common Stock | S | 205144 | $5.45 | Disposed | 3160284 | Indirect |
| 2018-01-26 | Common Stock | S | 39300 | $5.35 | Disposed | 3120984 | Indirect |
Footnotes
F1: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.